JP2022523018A - ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 - Google Patents

ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 Download PDF

Info

Publication number
JP2022523018A
JP2022523018A JP2021542124A JP2021542124A JP2022523018A JP 2022523018 A JP2022523018 A JP 2022523018A JP 2021542124 A JP2021542124 A JP 2021542124A JP 2021542124 A JP2021542124 A JP 2021542124A JP 2022523018 A JP2022523018 A JP 2022523018A
Authority
JP
Japan
Prior art keywords
phenebrutinib
treatment
patient
compound
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542124A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020154252A5 (https=
JP2022523018A5 (https=
Inventor
タミコ カツモト，
レスリー チン，
アリッサ モリモト，
デビッド ジェームズ ハドン，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2022523018A publication Critical patent/JP2022523018A/ja
Publication of JPWO2020154252A5 publication Critical patent/JPWO2020154252A5/ja
Publication of JP2022523018A5 publication Critical patent/JP2022523018A5/ja
Priority to JP2024062648A priority Critical patent/JP2024099575A/ja
Priority to JP2025189049A priority patent/JP2026041743A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021542124A 2019-01-22 2020-01-21 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 Pending JP2022523018A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024062648A JP2024099575A (ja) 2019-01-22 2024-04-09 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
JP2025189049A JP2026041743A (ja) 2019-01-22 2025-11-10 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US62/795,477 2019-01-22
US201962913270P 2019-10-10 2019-10-10
US62/913,270 2019-10-10
PCT/US2020/014346 WO2020154252A1 (en) 2019-01-22 2020-01-21 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062648A Division JP2024099575A (ja) 2019-01-22 2024-04-09 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法

Publications (3)

Publication Number Publication Date
JP2022523018A true JP2022523018A (ja) 2022-04-21
JPWO2020154252A5 JPWO2020154252A5 (https=) 2023-02-01
JP2022523018A5 JP2022523018A5 (https=) 2023-02-01

Family

ID=69726724

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021542124A Pending JP2022523018A (ja) 2019-01-22 2020-01-21 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
JP2024062648A Pending JP2024099575A (ja) 2019-01-22 2024-04-09 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
JP2025189049A Pending JP2026041743A (ja) 2019-01-22 2025-11-10 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024062648A Pending JP2024099575A (ja) 2019-01-22 2024-04-09 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
JP2025189049A Pending JP2026041743A (ja) 2019-01-22 2025-11-10 ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法

Country Status (11)

Country Link
US (1) US12544372B2 (https=)
EP (1) EP3914250A1 (https=)
JP (3) JP2022523018A (https=)
KR (1) KR20210119457A (https=)
CN (3) CN113423401A (https=)
AU (2) AU2020213265B2 (https=)
CA (1) CA3125236A1 (https=)
IL (1) IL284779A (https=)
MX (2) MX2021008696A (https=)
TW (1) TW202042815A (https=)
WO (1) WO2020154252A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP2020514384A (ja) 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT02833350, Safety and Efficacy Study of GDC-0853 Compared With Place", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6023053332, 18 October 2018 (2018-10-18), ISSN: 0005539508 *
"PROTOCOL: A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Acti", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6023053331, 10 March 2017 (2017-03-10), ISSN: 0005539509 *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 103, no. 6, JPN6023053333, 2018, pages 1020 - 1028, ISSN: 0005539507 *
J. MED. CHEM., vol. 61, no. 6, JPN6023053334, 2018, pages 2227 - 2245, ISSN: 0005539506 *

Also Published As

Publication number Publication date
AU2020213265A1 (en) 2021-07-22
MX2025013950A (es) 2026-03-02
IL284779A (en) 2021-08-31
MX2021008696A (es) 2021-08-19
TW202042815A (zh) 2020-12-01
CN113423401A (zh) 2021-09-21
KR20210119457A (ko) 2021-10-05
WO2020154252A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
AU2020213265B2 (en) 2025-01-16
AU2025201888A1 (en) 2025-04-03
CA3125236A1 (en) 2020-07-30
US12544372B2 (en) 2026-02-10
JP2026041743A (ja) 2026-03-10
EP3914250A1 (en) 2021-12-01
US20220047588A1 (en) 2022-02-17
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
Katarzyna et al. Current treatment of systemic lupus erythematosus: a clinician's perspective
Daien et al. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine
Riccaboni et al. Spleen tyrosine kinases: biology, therapeutic targets and drugs
JP2026041743A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
Grosso et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
TWI877239B (zh) 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
Lustig et al. Use of immunosuppressive agents in uveitis
Goropevšek et al. STAT signaling as a marker of SLE disease severity and implications for clinical therapy
US20250255874A1 (en) Methods for Treating Immune Thrombocytopenia By Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enentrile
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
CA3217278A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
HK40056367A (en) Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton’s tyrosine kinase
Breccia et al. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
US20240041870A1 (en) Methods of treating systemic lupus erythematosus
Raed Alzyoud., et al.“Unicentric Castleman’s Disease with Multicentric Behavior: A Case Report”
HK40113661A (zh) Cd40l特异性tn3衍生支架及其用於治疗和预防类风湿性关节炎的方法
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制
Combe et al. Double-blind comparison of Etanercept and Sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving Sulphasalazine
Sambrook et al. Etanercept and sulfasalazine, alone and combined

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241216